As with any rapidly evolving field, defining the scope and boundaries of regenerative medicine is a challenge. However, understanding this innovative industry requires examining the foundational components of the human body and the groundbreaking technologies designed to restore or enhance its function. To understand the definition of this scientific field, it is critical to understand the key components that compose the human body, which are: [Read more…]
RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions
Partnership pairs Applied StemCell’s induced pluripotent stem cell technology with RoosterBio’s engineered media, reagents, and scalable bioprocess systems to accelerate development and manufacturing of advanced therapies
MILPITAS, Calif. and FREDERICK, Md., July 8, 2026 — Applied StemCell, Inc., a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions, today announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions. The collaboration combines Applied StemCell’s GMP-compatible iPSC technology with RoosterBio’s engineered media systems and scalable manufacturing expertise to provide advanced therapy developers with a unique bioprocess solution supporting research through clinical manufacturing. [Read more…]
BBG Advanced Therapies Launches Mobile Leukapheresis Center in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients
BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas—marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells.
SAN ANTONIO, TX, July 7, 2026 – BBG Advanced Therapies, a subsidiary of nonprofit BioBridge Global (BBG), today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas — marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells. [Read more…]
RoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. Customers
Distribution agreement gives U.S. customers a single-vendor source for high-quality cells, bioprocess media, and recombinant growth factors—giving cell and exosome therapy developers a single, translation-friendly source for critical raw materialsÂ
FREDERICK, MD., July 7, 2026 — RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins. Under the agreement, customers in the United States can now order Qkine’s full range of translation-friendly research use only (RUO) growth factors and cytokines directly from RoosterBio. [Read more…]
What Stem Cell Clinics Do You Trust?
On a global basis, stem cell clinics have proliferated in recent years. This article explores stem cell centers within the U.S. and worldwide. Read on to learn about this emerging area of medicine. [Read more…]
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 339
- Next Page »